Luk Ho-Ming
Clinical Genetic Service, Department of Health, Kowloon, Hong Kong.
Case Rep Genet. 2016;2016:9790169. doi: 10.1155/2016/9790169. Epub 2016 Jan 28.
Epigenetic abnormalities in 15q11-13 imprinted region and UBE3A mutation are the two major mechanisms for molecularly confirmed Angelman Syndrome. However, there is 10% of clinically diagnosed Angelman Syndrome remaining test negative. With the advancement of genomic technology like array comparative genomic hybridization and next generation sequencing methods, it is found that some patients of these test negative Angelman-like Syndromes actually have alternative diagnoses. Accurate molecular diagnosis is paramount for genetic counseling and subsequent management. Despite overlapping phenotypes between Angelman and Angelman-like Syndrome, there are some subtle but distinct features which could differentiate them clinically. It would provide important clue during the diagnostic process for clinicians.
15q11 - 13印记区域的表观遗传异常和UBE3A突变是分子确诊的天使综合征的两种主要机制。然而,仍有10%临床诊断为天使综合征的患者检测呈阴性。随着阵列比较基因组杂交和下一代测序方法等基因组技术的进步,发现这些检测阴性的天使样综合征患者中有一些实际上有其他诊断。准确的分子诊断对于遗传咨询和后续管理至关重要。尽管天使综合征和天使样综合征之间存在重叠的表型,但仍有一些细微但明显的特征可在临床上区分它们。这将为临床医生在诊断过程中提供重要线索。